Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Lpath CEO, Scott Pancoast, to Present Live Online at RetailInvestorConferences.com on June 2 at 1 PM EDT

May 26, 2011 By Bio-Medicine.Org

NEW YORK, May 26, 2011 /PRNewswire/ — Lpath, Inc. (OTCBB:
LPTN), the industry leader in lipidomics-based therapeutics, will
present on RetailInvestorConferences.com on June 2, 2011 at 1:00 PM
EDT.

Lpath’s president and CEO, Scott Pancoast, will discuss the
company’s progress, including status updates on the PEDigree and
Nexus clinical trials, where the company’s ocular drug candidate,
iSONEP™, is being investigated in human proof-of-concept
studies.

To access, follow this link: www.retailinvestorconferences.com
and then click on: “Register/Watch Event Now!” Attendees are
advised to pre-register and receive event updates.

This will be a live, interactive online event where investors
are invited to ask the company questions in real-time in the
virtual “presentation hall.” After the presentation investors are
invited to ask questions and download shareholder materials from
the company’s “virtual booth.” A replay of the event will be
available for 90 days.

Lpath entered into an agreement with Pfizer in late 2010 that
provides Pfizer an exclusive option for a worldwide license to
develop and commercialize iSONEP for ocular indications. Pfizer and
Lpath are collaborating closely on the two iSONEP clinical
trials.

Pfizer also has a right of first refusal, which expires in late
2013, for Lpath’s cancer drug candidate, ASONEP™. Lpath is
planning to further investigate ASONEP in a Phase 2 trial involving
renal cell carcinoma patients and perhaps in a second trial
involving patients with prostate cancer or neuroblastoma.

About Lpath

San Diego-based Lpath, a therapeutic antibody company, is the
category leader in lipidomics-based therapeutics, an emerging field
of medicine that targets bioactive signaling lipids for treating a
wide range of human disease. Lpath’s ImmuneY2™ drug-discovery
engine has the unique ability to generate therapeuti

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech